Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer

This article was originally published here

Standard treatment options for patients with advanced or metastatic colorectal cancer include surgery when possible, chemotherapy with or without targeted therapy, and radiation therapy. However, many patients with

The post Daiichi Sankyo initiates phase 2 study of patritumab deruxtecan in advanced colorectal cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply